In This Issue
- Clinical Trial Spotlight-Trial #12-537 Ipilimumab for Patients Who Relapse after Allogeneic Transplantation - Patients with hematologic malignancies who relapse after allogeneic transplantation have few effective therapeutic options and generally have a poor prognosis.
- Immunomodulation in Multiple Myeloma - Effective cancer immunotherapy represents a major paradigm shift in the treatment of solid and hematologic malignancies. From the development of monoclonal antibodies (MoAb) to antibody-drug conjugates targeting cancer-associated epitopes until the most recent checkpoint blockade and bioengineered chimeric antigen receptor (CAR) T cells, the natural history of several types of cancer has been radically impacted by these treatments.
- PD-1 Blockade in Classical Hodgkin Lymphoma - Using the power of the human immune system to combat cancer has been a long-standing goal in oncology. In the last few years, an important milestone on the way to this goal has been the understanding of immune checkpoint pathways.
- Research Spotlight: New Frontiers in Cellular Therapies – 360 Degrees of Immuno-oncology - Allogeneic hematopoietic stem cell transplantation (HSCT) is the original cellular therapy. When HSCT is used for treatment of patients with leukemia and other hematologic malignancies, clinicians hope that polyclonal T cells from healthy donors will recognize tumor cells that the patient's own T cells do not, thereby exerting an anti-neoplastic "graft-versus-leukemia" (GvL) effect.